Please assess the completion status of the following clinical trial:

Trial Title: 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with biochemical progression during ADT or combination therapies including ADT who are referred for imaging evaluation (prostate specific antigen \[PSA\] level \>= 1 ng/ml that has increased on at least 2 successive occasions at least 1 weak apart)~* Patients with bone scan scheduled or performed~  * Within 30 days of the PSMA PET, without any new prostate cancer (PCa) therapy in between~ * Bone scans performed at University of California, Los Angeles (UCLA) and external institutions are eligible if Digital Imaging and Communications in Medicine (DICOM) images can be obtained, imported, and anonymized~* Patients enrolled in other clinical trials are eligible if they satisfy all other criteria of eligibility~* Patients or their legal representatives must have the ability to read, understand and provide written informed consent~Exclusion Criteria:~* Initiation of a new therapy between the PSMA PET/CT and the bone scans~* Inability to provide written informed consent~* Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (68Ga-PSMA-11 PET/CT) (Type: EXPERIMENTAL): Patients receive gallium Ga 68 gozetotide IV. After 50-100 minutes, patients undergo whole body PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).